Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus
Recruiting · NCT04432025 · Interventional (participants receive a specific treatment) · Lead sponsor: Imperial College London
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.
Who can take part
Inclusion criteria
- eligible for bariatric surgery according to NICE guidelines (GC 189)
- Type 2 diabetes mellitus
- BMI \>30kg/m2
Exclusion criteria
- Recent hospitalisation in the past 30 days
- Recurrent hypoglycaemic episodes
- Recurrent hypotensive episodes
- Contraindications to bariatric surgery
- Previous bariatric surgery
- Current pregnancy
- Breastfeeding
Where it is running
1 location listed.
- University College Dublin - Dublin, Ireland